Growth hormone response to arginine test differentiates between two subgroups of Huntington's disease patients

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 82, Issue 5, 2011, Pages 543-548

  Salvatore, Elena ^a   Rinaldi, Carlo ^a   Tucci, Tecla ^a   Maio, Luigi Di ^a   Somma, Carolina Di ^b   Savastano, Silvia ^a   Lombardi, Gaetano ^a   Filla, Alessandro ^a   Colao, Annamaria ^a   De Michele, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS SDN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GLUCOSE; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN B;

ADULT; AGED; ARTICLE; BODY MASS; CAG REPEAT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HOMEOSTASIS; HORMONE ACTION; HUMAN; HUNTINGTON CHOREA; HYPOTHALAMUS DISEASE; INSULIN METABOLISM; LIPID METABOLISM; MALE; NERVE DEGENERATION; PHENOTYPE; PRIORITY JOURNAL; RATING SCALE;

EID: 79953859059     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2010.208553     Document Type: Article

References (23)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 817-18.
2. Kassubek J, Juengling FD, Kioschies, et al. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry 2004; 75: 213-20. (Pubitemid 38183526)
3. Kremer HP, Roos RA, Dingjan GM, et al. The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease. Neurosci Lett 1991; 132: 101-4.
4. Timmers HJ, Swaab DF, van de Nes JA, et al. Somatostatin 1-12 immunoreactivity is decreased in the hypothalamic lateral tuberal nucleus of Huntington's disease patients. Brain Res 1996; 728: 141-8. (Pubitemid 26252805)
5. Morales LM, Estevez J, Suarez H, et al. Nutritional evaluation of Huntington disease patients. Am J Clin Nutr 1989; 50: 145-50. (Pubitemid 19195534)
6. Arnulf I, Nielsen J, Lohmann E, et al. Rapid eye movement sleep disturbances in Huntington disease. Arch Neurol 2008; 65: 482-8. (Pubitemid 351549956)
7. Morton AJ, Wood NI, Hastings MH, et al. Disintegration of the sleepewake cycle and circadian timing in Huntington's disease. J Neurosci 2005; 25: 157-63. (Pubitemid 40110776)
8. Aziz NA, Pijl H, Frolich M, et al. Increased hypothalamicepituitaryeadrenal axis activity in Huntington's disease. J Clin Endocrinol Metab 2009; 94: 1223-8.
9. Markianos M, Panas M, Kalfakis N, et al. Plasma testosterone in male patients with Huntington's disease: relations to severity of illness and dementia. Ann Neurol 2005; 57: 520-5. (Pubitemid 40471161)
10. Saleh N, Moutereau S, Durr A, et al. Neuroendocrine disturbances in Huntington's disease. Plos ONE. Published online first: 25 March 2009. doi: 10.1371/journal. pone.0004962.
11. Muller EE, Locatelli V, Cocchi D. Neuroendocrine control of growth hormone secretion. Physiol Rev 1999; 79: 511-607. (Pubitemid 29210930)
12. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998; 19: 717-97. (Pubitemid 128506521)
13. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society workshop on adult growth hormone deficiency. J Clin Endocrinol Metab 1998; 83: 379-81.
14. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11: 136-42.
15. Shoulson I, Odoroff C, Oakes D, et al. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann Neurol 1989; 25: 252-9. (Pubitemid 19085516)
16. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington's disease. Neurology 2000; 54: 452-8. (Pubitemid 30078083)
17. Biller BM, Samuels MH, Zagar A, et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 2002; 87: 2067-79. (Pubitemid 34521490)
18. Petersen A, Bjorkqvist M. Hypothalamic-endocrine aspects in Huntington's disease. Eur J Neurosci 2006; 24: 961-7. (Pubitemid 44268127)
19. Phillipson OT, Bird ED. Plasma growth hormone concentrations in Huntington's chorea. Clin Sci Mol Med 1976; 50: 551-4.
20. Grottoli S, Gasco V, Ragazzoni F, et al. Hormonal diagnosis of GH hypersecretory states. J Endocrinol Invest 2003; 26: 27-35.
21. Botfield C, Ross RJ, Hinds CJ. The role of IGFs in catabolism. Baillieres Clin Endocrinol Metab 1997; 11: 679-97. (Pubitemid 28200845)
22. Hawker FH, Stewart PM, Baxter RC, et al. Relationship of omatomedin-C/insulinlike growth factor I levels to conventional nutritional indices in critically ill patients. Crit Care Med 1987; 15: 732-6. (Pubitemid 18055657)
23. Politis M, Pavese N, Yen F Tai, et al. Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain 2008; 131: 2860-9.